Successful combination of Rituximab and plasma exchange in the treatment of cryoglobulinemic vasculitis with skin ulcers: A case report

Cases Journal

Volumn 2, Issue 7, 2009, Pages

  Tallarita, Tiziano ^a   Gagliano, Massimiliano ^a   Corona, Daniela ^a   Giuffrida, Giuseppe ^a   Giaquinta, Alessia ^a   Zerbo, Domenico ^a   Sorbello, Massimiliano ^a   Veroux, Pierfrancesco ^a   Veroux, Massimiliano ^a  

^a UNIVERSITY OF CATANIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

RITUXIMAB;

AGED; ANAMNESIS; ARTICLE; CASE REPORT; CRYOGLOBULINEMIA; DIABETES MELLITUS; HEPATITIS C; HOSPITAL ADMISSION; HUMAN; MALE; PLASMAPHERESIS; SKIN ULCER; VASCULITIS;

EID: 77953370060     PISSN: 17571626     EISSN: None     Source Type: Journal    
DOI: 10.4076/1757-1626-2-7859     Document Type: Article

References (15)

1. Lamprecht P, Moosig F, Gause A, Herlyn K, Csernok E, Hansen H, Gross WL: Immunological and clinical follow up of hepatitis C virus associated cryoglobulinaemic vasculitis. Ann Rheum Dis 2001, 60:285-290.
2. Agnello V, Chung RT, Kaplan LM: A role for hepatitis C virus infection in type II cryoglobulinemia. N Engl J Med 1992, 327:1490- 1495.
3. Carbonari M, Caprini E, Tedesco T, Mazzetta F, Tocco V, Casato M, Russo G, Fiorilli M: Hepatitis C virus drives the unconstrained monoclonal expansion of VH1-69-expression memory B cells in type II cryoglobulinemia: a model of infection-driven lymphomagenesis. J Immunol 2005, 174:6532-6539.
4. Misiani R, Bellavista P, Fenili D, Vicari O, Marchesi D, Sironi PL, Zilio P, Vernocchi A, Massazza M, Vendramin G, Tanzi E, Zanetti A: Interferon alpha-2° therapy in cryoglobulinemia associated with hepatitis C virus. N Engl J Med 1994, 330:751-756.
5. Casato M, Agnello V, Pupillo LP, Knight GB, Leoni M, Del Vecchio S, Mazzilli CG, Antonelli G, Bonomo L: Predictors of long-term response to high-dose interferon therapy in type II cryoglobulinemia associated with hepatitis C virus infection. Blood 1997, 90:3865-3873.
6. Sansonno D, De Re V, Lauletta G, Tucci FA, Boiocchi M, Dammacco F: Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon alpha with an anti-CD20. Blood 2003, 101:3818-3826.
7. Zaia F, De Vita S, Mazzaro C, Sacco S, Damiani D, De Marchi G, Michelutti A, Baccarani M, Fanin R, Ferraccioli G: Efficacy and safety of Rituximab in type II mixed cryoglobulinemia. Blood 2003, 101:3827-3834.
8. Lamprecht P, Lerin-Lozano C, Merz H, Dennin RH, Gause A, Voswinkel J, Peters SO, Gutzeit O, Arlt AC, Solbach W, Gross WL: Rituximab induces remission in refractory HCV associated cryoglobulinemic vasculitis. Ann Rheum Dis 2003, 62:1230-1233.
9. Roccatello D, Baldovino S, Rossi D, Mansouri M, Naretto C, Gennaro M, Cavallo R, Alpa M, Costanzo P, Giachino O, Mazzucco G, Sena LM: Long-term effects of anti-CD20 monoclonal antibody treatment of cryoglobulinaemic glomerulonephritis. Nephrol Dial Transplant 2004, 19:3054-3061.
10. Basse G, Ribes D, Kamar N, Mehrenberger M, Esposito L, Guitard J, Lavayssiere L, Oksman F, Durand D, Rostaing L: Rituximab therapy for de novo mixed cryoglobulinemia in renal transplant patients. Transplantation 2005, 80:1560-1564.
11. Quartuccio L, Soardo G, Romano G, Zaja F, Scott CA, De Marchi G, Fabris M, Ferraccioli G, De Vita S: Rituximab treatment for glomerulonephritis in HCV-associated mixed cryoglobulinemia: efficacy and safety in the absence of steroids. Rheumatology 2006, 45:842-846.
12. Reff ME, Carner K, Chambers KS, Chinn PC, Leonard JE, Raab R, Newman RA, Hanna N, Anderson DR: Depletion of B cells in vivo by chimeric mouse human monoclonal antibody to CD20. Blood 1994, 83:435-445.
13. Maloney DG, Grillo-Lopez AJ, White CA, Bodkin D, Schilder RJ, Neidhart JA, Janakiraman N, Foon KA, Liles TM, Dallaire BK, Wey K, Royston I, Davis T, Levy R: IDEC-C2B8 [rituximab] anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non Hodgkin lymphoma. Blood 1997, 90:2188-2195.
14. De Vita S, Zaja F, Sacco S, De Candia A, Fanin R, Ferraccioli G: Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis: evidence for a pathogenetic role of B cells. Arthritis Rheum 2002, 46:2029-2033.
15. Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, Stevens RM, Shaw T: Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004, 350:2572-2581.